4don MSN
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market
On Wednesday, Ionis Pharmaceuticals Inc. IONS said it is cutting the annual list price of its triglyceride-lowering drug Tryngolza (olezarsen) to $40,000 from $595,000. The move positions the therapy ...
Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for its investigational therapy zilganersen for Alexander disease. The designation follows pivotal data indicating meaningful ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic ...
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results